Clarification Regarding Diamyd's NP2 project
The Company would like to clarify that at this time there are no formal
partnership negotiations ongoing regarding NP2, as suggested in media. A
structured out-licensing process for NP2 is intended to be initiated
after results from a planned Phase II study in cancer patients are
available.
Diamyd announced earlier today that to date no drug related Serious
Adverse Events have been reported by any patient included in Diamyd's
Phase I clinical trial investigating NP2 as a potential therapy for
chronic pain. Based upon the Phase I findings to date, the company is
planning a multi-center, randomized, double-blind, placebo controlled
Phase II clinical trial with NP2 in the United States.
For more information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)
Phone: +46 8 661 0026
For pictures and press material, please contact:
Andreas Ericsson, Diamyd Medical AB (publ.)
andreas.ericsson@diamyd.com (andreas.ericsson@diamyd.com)
Phone: +46 8 661 0026
